Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Medicine
Published in: BMC Medicine 1/2014

Open Access 01-12-2014 | Forum

Personalized medicine: risk prediction, targeted therapies and mobile health technology

Authors: Daniel F Hayes, Hugh S Markus, R David Leslie, Eric J Topol

Published in: BMC Medicine | Issue 1/2014

Login to get access

Abstract

Personalized medicine is increasingly being employed across many areas of clinical practice, as genes associated with specific diseases are discovered and targeted therapies are developed. Mobile apps are also beginning to be used in medicine with the aim of providing a personalized approach to disease management. In some areas of medicine, patient-tailored risk prediction and treatment are applied routinely in the clinic, whereas in other fields, more work is required to translate scientific advances into individualized treatment. In this forum article, we asked specialists in oncology, neurology, endocrinology and mobile health technology to discuss where we are in terms of personalized medicine, and address their visions for the future and the challenges that remain in their respective fields.
Appendix
Available only for authorised users
Literature
1.
Beatson GW: On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896, 148: 104-107. 10.1016/S0140-6736(01)72307-0.CrossRef
2.
Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L: Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012, 9: 16-32.CrossRef
3.
Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344: 1031-1037. 10.1056/NEJM200104053441401.CrossRefPubMed
4.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N: A multi-gene RT-PCR assay using fixed, paraffin-embedded tumor tissue to predict the likelihood of breast cancer recurrence in node negative, estrogen receptor positive, tamoxifen-treated patients. N Engl J Med. 2004, 351: 2817-2826. 10.1056/NEJMoa041588.CrossRefPubMed
5.
Hassett MJ, Silver SM, Hughes ME, Blayney DW, Edge SB, Herman JG, Hudis CA, Marcom PK, Pettinga JE, Share D, Theriault R, Wong YN, Vandergrift JL, Niland JC, Weeks JC: Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol. 2012, 30: 2218-2226. 10.1200/JCO.2011.38.5740.CrossRefPubMedPubMedCentral
6.
Hayes DF, Allen J, Compton C, Gustavsen G, Leonard DG, McCormack R, Newcomer L, Pothier K, Ransohoff D, Schilsky RL, Sigal E, Taube SE, Tunis SR: Breaking a vicious cycle. Sci Transl Med. 2013, 5: 196cm196.CrossRef
7.
Institute of Medicine: Evolution of Translational Omics: Lessons Learned and the Path Forward. 2012, Washington, DC: The National Academies Press
8.
McShane L, Hayes DF: Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol. 2012, 30: 4223-4232. 10.1200/JCO.2012.42.6858.CrossRefPubMedPubMedCentral
9.
10.
Fisman EZ, Tenenbaum A: A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol. 2009, 8: 38-10.1186/1475-2840-8-38.CrossRefPubMedPubMedCentral
11.
Pozzilli P, Leslie RD, Chan J, De Fronzo R, Monnier L, Raz I, Del Prato S: The A1C and ABCD of glycaemia management in type 2 diabetes: a physician’s personalized approach. Diabetes Metab Res Rev. 2010, 26: 239-244. 10.1002/dmrr.1092.CrossRefPubMed
12.
Tsapas A, Matthews DR: N of 1 trials in diabetes: making individual therapeutic decisions. Diabetologia. 2008, 51: 921-925. 10.1007/s00125-008-0983-2.CrossRefPubMed
13.
McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, Woerle HJ: Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013, 36: 237-244. 10.2337/dc12-0706.CrossRefPubMedPubMedCentral
14.
Phung OJ, Scholle JM, Talwar M, Coleman CI: Effect of non-insulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010, 303: 1410-1418. 10.1001/jama.2010.405.CrossRefPubMed
15.
Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S, ADVANCE Collaborative Group: Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010, 363: 1410-1418. 10.1056/NEJMoa1003795.CrossRefPubMed
16.
Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS, American Diabetes Association, American College of Cardiology Foundation, American Heart Association: Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American diabetes association and a scientific statement of the American college of cardiology foundation and the American heart association. J Am Coll Cardiol. 2009, 53: 298-304. 10.1016/j.jacc.2008.10.008.CrossRefPubMed
17.
Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, Puente DM, De Leiva A, Yderstraede K, Beck-Neilsen H, Tuomilehto J, Sarti C, Thivolet C, Hadden D, Hunter S, Schernthaner G, Scherbaum WA, Williams R, Brophy S, Pozzilli P, Leslie RD, on behalf of the Action LADA consortium: Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. Diabetes Care. 2013, 36: 908-913. 10.2337/dc12-0931.CrossRefPubMedPubMedCentral
18.
Tahrani AA, Varughese GI, Scarpello JH, Hanna FW: Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated?. BMJ. 2007, 8: 508-512.CrossRef
19.
Topol E: The Creative Destruction of Medicine: How the Digital Revolution Will Create Better Health Care. 2012, New York: Basic Books
Metadata
Title
Personalized medicine: risk prediction, targeted therapies and mobile health technology
Authors
Daniel F Hayes
Hugh S Markus
R David Leslie
Eric J Topol
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2014
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/1741-7015-12-37

Other articles of this Issue 1/2014

BMC Medicine 1/2014 Go to the issue

Question and Answer

Video Q & A: Alcohol - a global problem. An interview with Ian Gilmore

Research article

A cohort study on the incidence and outcome of pulmonary embolism in trauma and orthopedic patients

Opinion

Reliable direct measurement of causes of death in low- and middle-income countries

Commentary

Are school-based mental health interventions for war-affected children effective and harmless?

Research article

A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment

Research article

Mental, neurological, and substance use problems among refugees in primary health care: analysis of the Health Information System in 90 refugee camps